German CAR-T spin-off names co-founder Ulf Grawunder as CEO

6 October 2022

T-CURX, a CAR-T cell spin-off from the University of Würzburg, has announced the appointment of its co-founder, Ulf Grawunder, as the chief executive of the company.

The German biotech firm was co-founded by Dr Grawunder alongside academics Michael Hudecek and Christoph Rader, from the University of Würzburg and the University of Florida, respectively.

"We have achieved the translation of our novel and superior CAR-T manufacturing platform to the stage of clinical trials in human patients"Dr Grawunder has a strong track record in founding and building biotech companies from the ground up and all the way toward an exit.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK